CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?
Capricor insiders sold shares before FDA decisions; CEO confident in data. Sellas director bought shares, gaining 430%. Iovance insiders made no trades; Q3 revenue up 80%. Institutional investors increased Sellas holdings, cut Capricor. Retail sentiment varies; IBRX up 237% YTD, CAPR down 61%.
How this was made
The 30-second read
Why it matters
Provides a snapshot of insider behavior but no fresh corporate disclosures; relevance is primarily informational.
Market read
Insider activity offers limited trading signals; investors should focus on upcoming FDA and trial outcomes.
What to watch
Upcoming FDA decisions and trial readouts could dominate price action more than past insider trades.
Background
The article aggregates recent insider trading activity and sentiment metrics for four listed biotech firms.
Ticker impact
Capricor insiders sold 1.9M shares in the quarter, reducing ownership despite 55% stake remaining.
potential downside as market prices in insider sales
Large insider sell in a micro‑cap biotech often precedes weaker near‑term sentiment.
Institutional investors cut IBRX holdings by 1.9M shares in the quarter, though they still own 55% of the company.
limited impact; price may stay flat to slightly lower
The reduction is modest relative to total holdings and no new operational news was disclosed.
Sellas director bought 63,400 shares at $100,806 on Nov.19, 2025, a 430% paper gain ahead of REGAL trial results.
upward bias as market views insider buying favorably
Director’s sizable purchase before a pivotal trial outcome often lifts sentiment.
Iovance insiders made no trades in the past year while Amtagvi sales rose 77% to $102M, boosting Q3 revenue.
price likely to hold; no immediate directional catalyst
Positive sales data exists but the article offers no new corporate event.
Market effects
Biotech sector sentiment may be modestly affected by insider activity across the four companies.
U.S. biotech micro‑caps could see slight volatility but no broad market shift.
Limited to investors tracking niche biotech equities.
Counterpoint
Insider sales may be routine portfolio rebalancing rather than a red flag.
Key entities
- companyCapricor Therapeutics
Biotech firm awaiting FDA decision for Duchenne therapy.
- companyImmunityBio
Biotech with institutional ownership changes.
- companySellas Life Sciences
Biotech advancing REGAL leukemia trial.
- companyIovance Biotherapeutics
Biotech with strong Amtagvi sales.

